335255-43-1

Basic information

• Product Name: CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester;tert-butyl 2-amino-4-(thiophen-2-yl)phenylcarbamate;tert-butyl (2-amino-4-(thiophen-2-yl)phenyl)carbamate(WX150097);tert-butyl N-(2-amino-4-thiophen-2-ylphenyl)carbamate
• CAS NO: 335255-43-1
• Molecular Formula: C₁₅H₁₈N₂O₂S
• Molecular Weight: 290.38062
• Mol File: 335255-43-1.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester(335255-43-1)
• EPA Substance Registry System: CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester(335255-43-1)

Safety Data

• Hazardous Substances Data: 335255-43-1(Hazardous Substances Data)

Usage

General Description

CarbaMic acid, N-[2-aMino-4-(2-thienyl)phenyl]-, 1,1-diMethylethyl ester is a chemical compound that is commonly known as carbaryl, which is a widely used insecticide. It belongs to the carbamate class of pesticides and is known for its broad spectrum of activity against various pests, including insects, mites, and nematodes. Its mode of action involves inhibiting the activity of the enzyme cholinesterase, which disrupts the transmission of nerve impulses in the nervous system of the target organisms, leading to paralysis and eventual death. Despite its effectiveness as a pesticide, carbaryl has been subject to controversy due to its potential toxicity to non-target organisms and its impact on human health and the environment. Therefore, its usage is regulated in many countries to minimize its adverse effects.

Upstream product

• 88-74-4 2-nitro-aniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 
• 875-51-4 4-Bromo-2-nitroaniline 
• 335254-95-0 tert-butyl (2-nitro-4-(thiophen-2-yl) phenyl)carbamate 

Downstream Products

• 1228793-70-1 BRD-9460 
• 1228793-77-8 BRD-3636 
• 1228793-80-3 BRD-7726 
• 1393745-21-5 N-(2-amino-5-(thiophen-2-yl)phenyl)-3-azido-5-(azidomethyl)benzamide 
• 1393745-24-8 N-(2-amino-5-(thiophen-2-yl)phenyl)-3-azido-4-(2-azidoethoxy)benzamide 
• 1393745-20-4 N-(2-amino-5-(thiophen-2-yl)phenyl)-4-azidobenzamide 
• 1609389-80-1 C₃₇H₄₃N₅O₅S 
• 1609390-00-2 C₂₈H₃₀N₄O₄S 
• 1609389-54-9 N-(2-amino-5-(thiophen-2-yl)phenyl)-8-cyclopropyl-7-morpholinoisoquinoline-3-carboxamide 
• 1609390-75-1 C₃₂H₃₄N₄O₄S 
• 1609389-56-1 N-(2-amino-5-(thiophen-2-yl)phenyl)-8-cyclopropyl-7-(piperazin-1-yl)isoquinoline-3-carboxamide 
• 1609390-81-9 C₃₇H₄₃N₅O₅S 
• 1609391-03-8 C₃₃H₃₈N₄O₄S 
• 1609391-51-6 N-(2-amino-5-(thiophen-2-yl)phenyl)-5-cyclopropyl-6-(piperazin-1-yl)-2-naphthamide 

Relevant articles and documents

Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study

Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study

Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In?vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.